GTx Announces Preliminary Results with Enobosarm

GTx, Inc. (Nasdaq: GTXI) today announced release of preliminary clinical data from its ongoing, open-label, Phase 2 clinical trial of enobosarm 3 mg (GTx-024) in postmenopausal women with stress urinary incontinence (SUI). An abstract entitled “Kegels In A Bottle”: Preliminary Results Of A Selective Androgen Receptor Modulator (GTx-024) For The Treatment Of SUI In Post-Menopausal Women, summarizing clinical data from the first seven patients completing 12 weeks of treatment with enobosarm, is now available on the International Continence Society’s website. This proof-of-concept clinical trial is the first of its kind to evaluate an orally-administered selective androgen receptor modulator (SARM) for SUI. Read more.

Source: BusinessWire, June 12, 2017

Third Randomized Controlled Trial (RCT) of the Vesair™ Bladder Control System For the Treatment of Stress Urinary Incontinence Delivers Promising Results

Solace Therapeutics, Inc., today announced that data from a multicenter 221 patient randomized controlled trial has met study endpoints with statistical significance. Dr. Eric Rovner will be presenting a poster of the results from the SUCCESS Clinical Trial at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) meeting in Scottsdale, Arizona on Thursday, March, 2^nd. This is the Company’s third randomized controlled trial to evaluate the safety and efficacy of the Vesair Bladder Control System; a novel, office-based, reversible treatment designed to reduce or eliminate urine leakage in female patients with Stress Urinary Incontinence (SUI). Read more.

Source: Business Wire, March 1, 2017

Patients with Urinary Incontinence, Who Have Multiple Sclerosis or Spinal Cord Injury

Clinical Trial News. If your urinary incontinence is related to MS or Spinal Cord Injury, you may qualify for a new clinical trial. Learn more about this new treatment and see if you may qualify for the trial here.

Source: Antidote, October 13, 2016

BioLife Products Embedded in Cook MyoSite Phase 3 Cell Therapy Trial for Stress Urinary Incontinence

BioLife Solutions, Inc.(BioLife, a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that its media products are embedded into the autologous cell therapy being developed by Pittsburgh-based Cook MyoSite, a subsidiary of the Cook Group, for treatment of female stress urinary incontinence. Read more.

Source: PharmaBiz.com, July 19, 2016